Form 4: Ultragenyx Director Deborah Dunsire Reports Acquisition of Shares and Stock Options

Director Deborah Dunsire reports acquisition of Ultragenyx Pharmaceutical Inc. shares and stock options.

Summary

• On May 15, 2025, Director Deborah Dunsire acquired 5,740 shares of Ultragenyx Pharmaceutical Inc. common stock at $0 per share.
• Following the transaction, Dunsire directly owns 30,815 shares of common stock.
• Dunsire also acquired stock options for 10,787 shares of common stock at an exercise price of $34.84, exercisable starting May 15, 2025, and expiring on May 15, 2035.
• These options also vest in full on the earlier of the Company's next Annual Meeting of Stockholders or May 15, 2026.
• The acquisition of shares was through an award of Restricted Stock Units (RSUs) under the Company's 2023 Incentive Plan, which vest in full on the earlier of the Company's next Annual Meeting of Stockholders or May 15, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. Insider buying is generally viewed positively, but this is part of a compensation plan.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting schedule tied to the Annual Meeting of Stockholders or May 15, 2026, aligns the director's interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• The acquisition of shares and stock options by a director can positively influence shareholder confidence.

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc., Director, Deborah Dunsire, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, RARE